Biogen · 5 days ago
Senior Clinical Development Lead, Immunology and Indication Expansion, WCH
San Francisco, CA
Full-time
Hybrid
Senior Level
$254K/yr - $349K/yr
6+ years expBiogen is a mid-sized biotechnology company focused on transforming the lives of patients with severe immune-mediated diseases. The Senior Clinical Development Lead will lead the development of early-phase immunology programs and indication expansion opportunities, driving high-priority clinical programs across all stages of development.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Lead the design and execution of one or more immunology or neuroimmunology/autoimmune programs from First-in-Human through Proof of Biology, pivotal trials, global registration, and life-cycle expansion. This includes accountability for timelines, risk mitigation, and key deliverables such as protocol development, study monitoring, data review, and analysis
Provide leadership to cross-functional project teams with peers from clinical operations, biometrics, clinical pharmacology, biomarker sciences, regulatory affairs, and medical writing, and others
Serve or oversee as medical monitor for early phase clinical trials, ensuring patient safety, protocol adherence, and timely issue resolution
Establish and maintain relationships with key opinion leaders and clinical investigators in the immunology field and disease areas related to active or prospective clinical development programs
Build and lead a high-performing clinical development team, including all phases of development addressing different immunology indications
Qualification
Required
MD, PhD, or PharmD is required
At least 6 years of experience in the biotech/pharmaceutical industry with additional experience in clinical or academic research
Proven track record of leading registration-stage programs or early clinical development programs with experience filing INDs
Experience interacting with global regulatory authorities
Deep scientific and clinical understanding of neuroimmunology/autoimmune disorders
Demonstrated ability to work effectively with cross-functional R&D partners
Experience leading cross-functional teams and mentoring clinical development professionals
Strong interpersonal skills, with the ability to establish and maintain relationships through a highly collaborative approach
Strong problem-solving, conflict resolution, and analytical skills
Ability to facilitate discussions among cross-functional groups and drive decisions on complex issues
Ability to travel domestically and internationally, approximately 10-20% of the time
Preferred
Subspecialty expertise in endocrinology or neuroimmunology, or prior drug development experience in these therapeutic areas, is strongly preferred
Established network of global Key Opinion Leaders (KOLs)
Benefits
Medical, Dental, Vision, & Life insurances
Fitness & Wellness programs including a fitness reimbursement
Short- and Long-Term Disability insurance
A minimum of 15 days of paid vacation and an additional end-of-year shutdown time off (Dec 26-Dec 31)
Up to 12 company paid holidays + 3 paid days off for Personal Significance
80 hours of sick time per calendar year
Paid Maternity and Parental Leave benefit
401(k) program participation with company matched contributions
Employee stock purchase plan
Tuition reimbursement of up to $10,000 per calendar year
Employee Resource Groups participation
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Founded in 1978Cambridge, Massachusetts, USA
5001-10000 employees
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (100)
2024 (93)
2023 (101)
2022 (134)
2021 (104)
2020 (114)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Robin C. Kramer
Executive Vice President, Chief Financial Officer
Priya Singhal
Executive Vice President, Head of Development
Recent News
2026-01-13
2026-01-13
2026-01-13
Company data provided by crunchbase